Last $17.37 USD
Change Today +0.19 / 1.11%
Volume 95.5K
As of 10:49 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

nxstage medical inc (NXTM) Snapshot

Open
$17.10
Previous Close
$17.18
Day High
$17.62
Day Low
$17.08
52 Week High
01/27/15 - $19.19
52 Week Low
05/7/14 - $10.69
Market Cap
1.1B
Average Volume 10 Days
310.3K
EPS TTM
$-0.40
Shares Outstanding
62.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NXSTAGE MEDICAL INC (NXTM)

Related News

No related news articles were found.

nxstage medical inc (NXTM) Related Businessweek News

No Related Businessweek News Found

nxstage medical inc (NXTM) Details

NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures. Its primary product is the NxStage System One, a portable hemodialysis system used for the treatment of acute and chronic kidney failure, and fluid overload. The company operates in two segments, System One and In-Center. The System One segment sells and rents the NxStage System One and PureFlow SL dialysate preparation equipment. This segment also sells extracorporeal disposable products, which are primarily used for in-center dialysis treatments for patients with end-stage renal disease (ESRD) in the home and critical care markets. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers; and needles for apheresis. NxStage Medical, Inc. markets its products through direct sales force and distributors to hospitals and dialysis centers in the United States and internationally. The company, formerly known as QB Medical, Inc., was founded in 1998 and is headquartered in Lawrence, Massachusetts.

3,400 Employees
Last Reported Date: 02/26/15
Founded in 1998

nxstage medical inc (NXTM) Top Compensated Officers

Founder, Chief Executive Officer and Director
Total Annual Compensation: $437.1K
President
Total Annual Compensation: $308.4K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $136.3K
President of Nxstage Kidney Care, Inc
Total Annual Compensation: $295.1K
Senior Vice President of Quality Assurance, R...
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2013.

nxstage medical inc (NXTM) Key Developments

Nxstage Medical, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the First Quarter and Full Year of Fiscal 2015

Nxstage Medical, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, revenues were $79,911,000 against $69,450,000 a year ago. Loss from operations was $4,473,000 against $4,578,000 a year ago. Net loss before income taxes was $4,694,000 against $4,796,000 a year ago. Net loss was $4,974,000 against $5,176,000 a year ago. Net loss attributable to stockholders of the company was $4,852,000 against $5,176,000 a year ago. Net loss per share, basic and diluted was $0.08 against $0.08 a year ago. For the full year, revenues were $301,501,000 against $263,429,000 a year ago. Loss from operations was $22,187,000 against $17,798,000 a year ago. Net loss before income taxes was $23,060,000 against $18,806,000 a year ago. Net loss was $24,313,000 against $18,561,000 a year ago. Net loss attributable to stockholders of the company was $23,946,000 against $18,561,000 a year ago. Net loss per share, basic and diluted was $0.39 against $0.31 a year ago. Net cash used in operating activities was $20,273,000 against $10,141,000 a year ago. The company spent about $13 million in CapEx in 2014. For the full year of fiscal 2015, the company is forecasting revenue to be between $324.0 million and $328.0 million. The company also expects a net loss in the range of $20.0 million to $24.0 million. The company planning around $5 million this year so a reduction in CapEx. For the first quarter of fiscal 2015, the company is forecasting revenue to be between $77.5 million and $78.5 million. The company also expects a net loss in the range of $6.5 million to $7.5 million. The majority of the company's projected net loss in both periods is expected to be related to the company's investment in NxStage Kidney Care.

Nxstage Medical, Inc. to Report Q4, 2014 Results on Feb 26, 2015

Nxstage Medical, Inc. announced that they will report Q4, 2014 results at 9:00 AM, US Eastern Standard Time on Feb 26, 2015

Nxstage Medical, Inc., Q4 2014 Earnings Call, Feb 26, 2015

Nxstage Medical, Inc., Q4 2014 Earnings Call, Feb 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NXTM:US $17.37 USD +0.19

NXTM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $19.06 USD +0.46
Cyberonics Inc $68.64 USD +0.14
ICU Medical Inc $90.00 USD +1.09
Merit Medical Systems Inc $19.75 USD +0.14
Orthofix International NV $32.48 USD +0.05
View Industry Companies
 

Industry Analysis

NXTM

Industry Average

Valuation NXTM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.5x
Price/Book 5.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NXSTAGE MEDICAL INC, please visit www.nxstage.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.